CEL-SCI Has Been "Almost There" Since Before Your Kids Were Born. Is This Time Different?

# CEL-SCI Has Been "Almost There" Since Before Your Kids Were Born. Is This Time Different?

Here's a fun exercise: pull up CEL-SCI's chart. It'll take you from $13.48 down to $1.14, a slow-motion bleed that makes you wonder how a company keeps the lights on for this long without a single dollar of product revenue. The answer, as always with CEL-SCI, is the same story that's been told for two decades: Multikine is almost there. This time it's really, actually, no-kidding almost there.

I want to believe it. The desk wants to believe it. Let's go through why, and then why you should still keep your hand on your wallet.

The Bull Case, Fairly Stated

Multikine has real data behind it — a 73% five-year overall survival rate versus 45% for standard of care alone in the target head-and-neck cancer population. That's not a rounding error, that's the kind of number that gets oncologists' attention if it holds up in a confirmatory setting. And CEL-SCI is finally running that confirmatory trial: a 212-patient Phase 3 study launched this summer, managed by CRO Ergomed across multiple countries, aimed squarely at FDA registration.

Then there's the Saudi angle. The Amarox partnership — signed with fanfare at BIO 2026 in San Diego — gives CEL-SCI a 50/50 revenue split in the Saudi market with a partner the SFDA has ranked #1 for "critical and unavailable medicine" three years running. It's a legitimate dual-track regulatory play: chase the FDA in the U.S. while building a parallel commercial runway in Saudi Arabia through the SFDA. That's smart structuring for a company that can't afford to bet everything on one regulator's calendar.

And CEO Geert Kersten just bought 400,000 shares for roughly $480,000, bringing his personal buying over ten months to nearly $930,000. Insiders don't usually write checks that size into a stock trading near its 52-week low unless they believe something. That's worth noting. It is not, by itself, worth backing up the truck.

The Bear Case, Which Is Doing Most of the Talking

Here's the problem: none of the above changes the balance sheet. CEL-SCI posted a $5.5 million net loss in its most recent quarter, on top of a $5.5 million loss the quarter before that. Free cash flow is deeply negative. Debt-to-equity sits north of 123. Return on equity is running at roughly -305%. This is not a company with a cash-flow problem — it's a company whose entire existence is a cash-flow problem, permanently solved by issuing more stock.

And that's exactly what's happening. A $7.2 million financing in May, followed by a priced offering in June — this is a company that funds its trials one dilutive raise at a time. The CEO's stock purchases look better in that light, but they don't offset the fact that shareholders keep getting diluted to keep the lab lights on. Institutional ownership is a thin 4.45%, which tells you the smart-money crowd isn't exactly piling in to underwrite this story either.

Then there's the trial itself. A 212-patient study spread across multiple continents is an execution nightmare even for well-capitalized biotechs — site selection, enrollment timelines, data consistency. CEL-SCI is attempting this while running on fumes. Any slippage in enrollment or a soft readout, and the equity has nothing underneath it.

Where That Leaves You

The setup here is genuinely binary. If Multikine's confirmatory data lands anywhere close to that 73%/45% split, this stock — at $1.14 — is priced like a company already given up on. Bull-case price targets sitting around $5.75 aren't crazy in that scenario. But the base case, reflecting the actual financial condition of the business, is sitting closer to $0.57. That's the tension: a legitimate scientific story trapped inside a balance sheet that's been running on fumes and financings for years.

I'm not chasing the $25 price target some retail corners are floating — that number belongs in a different valuation model than the one this company's cash flow statement supports. If you want exposure to the Phase 3 catalyst, do it small, do it knowing dilution is the house style here, and don't confuse an insider buying shares with a company that's suddenly solvent. CEL-SCI has been "almost there" for a very long time. It might finally be there. But bring a stop-loss, not a mortgage.